Reports
Reports
Sale
The global vaccine market was valued at USD 68.07 billion in 2023, driven by the rising prevalence of infectious diseases across the globe. The market is expected to grow at a CAGR of 10.5% during the forecast period of 2024-2032, with the values likely to rise from USD 75.22 billion in 2024 to USD 167.19 billion by 2032.
Emerging and recurring infectious diseases pose a serious threat to the global economy. The development of vaccines is considered an effective countermeasure to ensure pandemic control. Administered as a preventive measure instead of a treatment, vaccines train the immune system to produce antibodies when exposed to a disease. The vaccines market demand is driven by the emphasis to mitigate any outbreak risks against infectious diseases such as COVID-19, tuberculosis, dengue, and cholera in the coming years.
The data released by the CDC (Centers for Disease Control and Prevention) on global immunization depicts the efficacy of vaccines. The statistics reveal that childhood vaccination prevents 4 million deaths every year. It is estimated that over 50 million deaths can be prevented with the help of immunization by 2030. In addition, around 19 million lives can be saved by measles vaccination whereas, hepatitis B vaccination can prevent 14 million deaths. The criticality of accelerating the vaccine development has been recognized by the government. Consequently, vigorous campaigns and initiatives aimed at vaccine innovation and development are anticipated to elevate vaccine market share in the forecast period.
Surge in Vaccine Approvals by the Health Authorities
To provide enhanced protection against severe consequences of infectious diseases, health authorities such as the United States Food and Drug Administration (FDA) are approving vaccines that are safe and effective at an accelerated rate. In September 2023 , the FDA approved an updated COVID-19 vaccine (2023-2024 formula corresponding to the omicron variant XBB.1.5 of SARS-CoV-2) developed by Pfizer, a multinational biotechnology corporation, and Biopharmaceutical New Technologies (BioNTech), a German biotechnology company. Administered in individuals aged 5 years or above, this vaccine is taken as a single dose and is tailored against the current circulating variants of the coronavirus. With the surge in vaccine approvals by the health authorities, the market value is expected to witness notable growth in the forecast period.
Increased Funding to Expedite Vaccine Development
Strategic investment decisions of firms, private investors, government, and non-profit organizations can significantly bolster vaccine market growth. In June 2023, Wellcome (a global charitable foundation) and the Bill & Melinda Gates Foundation announced USD 550 million funding for a phase III clinical trial for a tuberculosis vaccine candidate, M72 (M72/AS01E). The clinical trial covering 26,000 people spanning 50 sites across Africa and Southeast Asia will begin in early 2024 and is expected to complete in 4-6 years. Since tuberculosis is the second leading infectious killer after COVID-19, Wellcome agreed to provide USD 150 million while the rest of USD 400 million was covered by the Bill & Melinda Gates Foundation.
Intensive Research to Develop Cancer Vaccine
The rise in the number of cancer patients is prompting the development of personalized cancer vaccines. It is estimated that 30 million new cancer cases will be diagnosed by 2040 if appropriate measures are not taken to control and prevent cancer. To address these concerns, researchers are trying to develop cancer vaccines that can induce the immune system to show a triggered response against cancer cells. This rising focus on the production of novel vaccines is expected increase the vaccine market size in the forecast period.
In April 2023, a Norwegian biotechnology company, Nykode Therapeutics announced that its Phase IIa trial of the cervical cancer vaccine, VB10.16, yielded positive results. The reports showed that 52 patients (having advanced or recurrent, non-resectable cervical cancer caused by the HPV16 virus) who underwent the clinical trial had a median overall survival of 16.9 months. Thus, Nykode’s plasmid DNA-based vaccine increased survival in advanced cervical cancer patients and is expecting a larger trial in 2024.
Vaccine Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Vaccine Market Overview
3.1 Global Vaccine Market Historical Value (2017-2023)
3.2 Global Vaccine Market Forecast Value (2024-2032)
4 Global Vaccine Market Landscape*
4.1 Global Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Vaccine Product Landscape
4.2.1 Analysis by Indication
4.2.2 Analysis by Technology
5 Global Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Vaccine Market Segmentation (2017-2032)
6.1 Global Vaccine Market (2017-2032) by Indication
6.1.1 Market Overview
6.1.2 Pneumococcal
6.1.3 Influenza
6.1.4 DTP
6.1.5 HPV
6.1.6 MMR
6.1.7 COVID-19
6.2 Global Vaccine Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Recombinant
6.2.3 Toxoid
6.2.4 Conjugate
6.2.5 RNA
6.3 Global Vaccine Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Adult
6.3.3 Children
6.4 Global Vaccine Market (2017-2032) by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital and Clinical Pharmacies
6.4.3 Retail Pharmacies
6.4.4 Online Pharmacies
6.5 Global Vaccine Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Vaccine Market (2017-2032)
7.1 North America Vaccine Market (2017-2032) by Indication
7.1.1 Market Overview
7.1.2 Pneumococcal
7.1.3 Influenza
7.1.4 DTP
7.1.5 HPV
7.1.6 MMR
7.1.7 COVID-19
7.2 North America Vaccine Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Recombinant
7.2.3 Toxoid
7.2.4 Conjugate
7.2.5 RNA
7.3 North America Vaccine Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Vaccine Market (2017-2032)
8.1 Europe Vaccine Market (2017-2032) by Indication
8.1.1 Market Overview
8.1.2 Pneumococcal
8.1.3 Influenza
8.1.4 DTP
8.1.5 HPV
8.1.6 MMR
8.1.7 COVID-19
8.2 Europe Vaccine Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Recombinant
8.2.3 Toxoid
8.2.4 Conjugate
8.2.5 RNA
8.3 Europe Vaccine Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Vaccine Market (2017-2032)
9.1 Asia Pacific Vaccine Market (2017-2032) by Indication
9.1.1 Market Overview
9.1.2 Pneumococcal
9.1.3 Influenza
9.1.4 DTP
9.1.5 HPV
9.1.6 MMR
9.1.7 COVID-19
9.2 Asia Pacific Vaccine Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Recombinant
9.2.3 Toxoid
9.2.4 Conjugate
9.2.5 RNA
9.3 Asia Pacific Vaccine Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Vaccine Market (2017-2032)
10.1 Latin America Vaccine Market (2017-2032) by Indication
10.1.1 Market Overview
10.1.2 Pneumococcal
10.1.3 Influenza
10.1.4 DTP
10.1.5 HPV
10.1.6 MMR
10.1.7 COVID-19
10.2 Latin America Vaccine Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Recombinant
10.2.3 Toxoid
10.2.4 Conjugate
10.2.5 RNA
10.3 Latin America Vaccine Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Vaccine Market (2017-2032)
11.1 Middle East and Africa Vaccine Market (2017-2032) by Indication
11.1.1 Market Overview
11.1.2 Pneumococcal
11.1.3 Influenza
11.1.4 DTP
11.1.5 HPV
11.1.6 MMR
11.1.7 COVID-19
11.2 Middle East and Africa Vaccine Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Recombinant
11.2.3 Toxoid
11.2.4 Conjugate
11.2.5 RNA
11.3 Middle East and Africa Vaccine Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Merck & Co. Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 GlaxoSmithKline Plc
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sanofi Aventis
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Novartis AG
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Pfizer Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Takeda Pharmaceutical Company Limited
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 DAIICHI SANKYO COMPANY, LIMITED
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Mitsubishi Chemical Group Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 AstraZeneca
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 MASSACHUSETTS BIOTECHNOLOGY COUNCIL
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Biokangtai
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 VBI Vaccines Inc
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Fei Biological
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Indian Immunologicals Ltd.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 68.07 billion in 2023, driven by the rising prevalence of infectious diseases across the globe.
The market is anticipated to grow at a CAGR of 10.5% during the forecast period of 2024-2032, likely to reach a market value of USD 167.19 billion by 2032.
The market demand is driven by substantial improvements in the healthcare infrastructure and increased awareness about the effectiveness of vaccines in preventing diseases.
The emphasis on treating chronic diseases with the help of vaccinations is a key market trend. In April 2023, a Norwegian biotechnology company, Nykode Therapeutics announced that its cervical cancer vaccine, VB10.16, showed increased survival in advanced cervical cancer patients in a Phase IIa clinical trial.
The market is divided into pneumococcal, influenza, DTP, HPV, MMR, and COVID-19.
The various end users of vaccines include adults and children.
Recombinant, toxoid, conjugate, and RNA among others, are the vaccine technologies available in the market.
The various distribution channels include hospital and clinical pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
Key players involved in the market are Merck & Co. Inc., GlaxoSmithKline Plc, Sanofi Aventis, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, DAIICHI SANKYO COMPANY, LIMITED, Mitsubishi Chemical Group Corporation, AstraZeneca, MASSACHUSETTS BIOTECHNOLOGY COUNCIL, Biokangtai, Serum Institute of India Pvt. Ltd., VBI Vaccines Inc., Fei Biological and Indian Immunologicals Ltd.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.